SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Sales of Investments

Cash received from selling or redeeming investments.

SNDL Inc.NASDAQ: SNDL

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of CA$116K fell 99.6% year over year, behind the -30.2% change in trailing-twelve-month sales of investments. Sequentially, it fell 96.4% from the prior quarter.

Context

  • Sales of investments amounted to 4.8% of revenue in FY2025, up 4.8 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -99.6% toward the trailing-twelve-month pace of -30.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$116K-96.4% QoQ
Last fiscal yearDec 2025
CA$45.58M— YoY
LTMMar 2026
CA$18.79M-30.2% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.6%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

CAD · from the cash flow

Latest · FY2025
45.58M CAD
Year-over-year change
—
4-year CAGR
+43.7%

Sales of Investments vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -30.2% is the lowest of 3, against a peer median of +36.0%.
  • Sales of investments amounts to 2.0% of revenue for SNDL, versus a peer median of 0.0%.
SNDL Competitors
Sales of Investments for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$321.66M USD-6.3%+4.1%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$89.12M USD+78.3%+24.9%—
SNDLSNDL Inc.LTM Mar 2026CA$18.79M CAD-30.2%—2.0%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
ESPREsperion Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
EOLSEvolus, Inc.LTM Mar 2026$0 USD——0.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$0 USD——0.0%
SIGASIGA Technologies, Inc.LTM Mar 2026$0 USD——0.0%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SNDL) —+36.0%+14.5%0.0%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(230.18M)(372.43M)(176.55M)(96.2M)(15.77M)
Depreciation & Amortization9.6M47.32M64.95M56.71M56.27M
Deferred Income Tax(2.27M)(7.34M)0(9.41M)0
Stock-Based Compensation12.31M9.67M15.4M20.04M13.91M
Change in Working Capital(1.53M)(22.07M)(32.88M)(7.45M)1.43M
Accounts Receivables00000
Inventory16.98M7.01M000
Accounts Payables00000
Other Working Capital(18.51M)(29.09M)(32.88M)(7.45M)1.43M
Other Non-Cash Items56.64M338.14M112.43M91.22M15.08M
Operating Cash Flow(155.44M)(6.71M)(16.65M)54.91M70.92M
Capital Expenditures(3.79M)(10.86M)(7.93M)(11.02M)(12.81M)
Acquisitions (Net)(478.34M)(147.78M)(21.39M)(39.48M)(3M)
Purchases of Investments(24.21M)(75.6M)(732K)0(16.41M)
Sales of Investments10.68M00045.58M
Other Investing Activities(612K)4.07M5.15M65.85M4.1M
Investing Cash Flow(496.28M)(230.16M)(24.82M)17.76M17.45M
Debt Repayment(10.36M)(37.69M)(41.01M)(36.95M)(39.25M)
Common Stock Issued1.06B22K000
Common Stock Repurchased0(13.39M)(1.54M)(13.28M)(15.35M)
Dividends Paid00000
Other Financing Activities97.65M9.27M(531K)871K106K
Financing Cash Flow1.15B(41.79M)(43.08M)(49.36M)(54.49M)
Effect of Forex Changes(9K)0000
Net Change in Cash497.88M(278.67M)(84.55M)23.32M33.88M
Free Cash Flow(159.23M)(17.57M)(24.58M)43.9M58.11M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.